Skip to main content
2024 ISPE Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Ghadeer Dawwas, PhD

Posdoctoral Research Fellow
University of Pennsylvania
Nashville, United States

Ghadeer Dawwas, PhD, MSc, MBA, is an Assistant Professor of Medicine in the Division of Epidemiology, Department of Medicine, at Vanderbilt University Medical Center. She is a Faculty Scholar at the Vanderbilt Center for Health Services Research (CHSR), and a member of Vanderbilt Translational and Clinical Cardiovascular Research Center (VTRACC).

Dr. Dawwas holds PhD and MSc degrees in pharmacoepidemiology from the University of Florida, an MBA from Stratford University, and a bachelor’s in pharmacy from the University of Jordan. She completed her postdoctoral fellowship at the Perelman School of Medicine at the University of Pennsylvania.

Dr. Dawwas is a pharmacoepidemiologist and her research program uses readily available healthcare data to provide stakeholders including patients, clinicians, payers, and policymakers with evidence on the risk/benefit tradeoffs of therapeutic alternatives to improve clinical decision-making. The major themes of her research center on the evaluation of anticoagulants, research methods, and the intersection of comparative effectiveness research and health policy. Her most notable contribution stems from the work that evaluated apixaban and rivaroxaban in patients with venous thromboembolism (VTE) that, among other evidence, led CVS Caremark to reverse its decision regarding the removal of apixaban from CVS preferred formulary list.

Dr. Dawwas' work resulted in notable peer-reviewed manuscripts published in Annals of Internal Medicine, Diabetes Care, and Lancet Hematology. She is a section editor of the Journal of Thrombosis and Thrombolysis. Currently, she serves as the PI of two grants funded by the National Heart, Lung, and Blood Institute (NHLBI) and the American Society of Hematology (ASH) that aim to improve VTE treatment and prevention in populations under-represented or excluded from randomized clinical trials.

Disclosure information not submitted.

Presentation(s):